医学
结直肠癌
疾病
生活质量(医疗保健)
肿瘤进展
肿瘤科
重症监护医学
第一行
内科学
治疗方法
癌症
护理部
作者
Carlotta Antoniotti,Roberto Moretto,Daniele Rossini,Gianluca Masi,Alfredo Falcone,Chiara Cremolini
标识
DOI:10.1016/j.ctrv.2020.102135
摘要
Prolonging survival, achieving symptoms palliation and preserving quality of life are the primary therapeutic goals of treatments administered after disease progression in mCRC. Even if the impact of these therapies on the prognosis of affected patients is less relevant than the impact of the upfront treatment, tailoring the optimal second-line therapy is increasingly important. Several therapeutic options are available, and different factors including not only patient- and disease-related characteristics, but also the first-line treatment received (i.e., type, timing of disease progression, observed outcome and reported toxicities) may drive this choice. Herein, we describe the current state of the art in the landscape of treatments after progression in mCRC. Based on a critical review of the literature, we built a patient-oriented therapeutic algorithm, aiming to guide clinicians in their daily decision-making.
科研通智能强力驱动
Strongly Powered by AbleSci AI